



sienna
CANCER DIAGNOSTICS

Sienna Cancer Diagnostics

2019 Annual General Meeting



- AGM
 - Chairman's Opening
 - Business of meeting including resolutions
- CEO Presentation
- Questions
- Tea / Coffee



sienna
CANCER DIAGNOSTICS

Annual General Meeting
Nov 14th 2019

- Annual Report

- To table and consider the 2019 Annual Report including the Financial Report, and the reports of the Directors and of the Auditors for the year ended 30 June 2019

No resolution is required for this item of business

- Adoption of the Remuneration Report

- To consider and, if thought fit, to pass the following non-binding resolution:

Resolution 1:

That the Company's Remuneration Report for the year ended 30 June 2019 as set out in the Company's Annual Report for the year ended 30 June 2019 be adopted

- Amendments to the Company Constitution

- To consider and, if thought fit, to pass the following resolution as a **special resolution**:

Resolution 3:

That Shareholders approve and ratify the amendments to the company constitution outlined in the Explanatory Memorandum which accompanies this Notice of Meeting

- Approval of increased placement capacity
 - To consider, and if thought fit, to pass the following resolution as a **special resolution**:

Resolution 4:


That pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, Shareholders approve an increase in the capacity of the Company to issue equity securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions stated in the Explanatory Memorandum which accompanies this Notice of Meeting

SIENNA CANCER DIAGNOSTICS



CEO Presentation
November 2019

OVERVIEW



GOAL

- Develop and commercialise a portfolio of diagnostic tests utilising Sienna's proprietary platforms to enable early, accurate diagnosis of cancer
- Establish a pipeline of products for sustainable long-term growth



CURRENT TECHNOLOGIES

- 2 existing technologies in the portfolio, SIEN-NET™ & hTERT
- SIEN-NET™ biological purification platform
- hTERT, diagnostic test for a unique cancer biomarker that assists in early bladder cancer detection



GROWTH STRATEGY

- SIEN-NET™ & EXO-NET™ commercialisation
- Acquire other platform technologies
- Expanding hTERT franchise through market share growth and geographical expansion

GROWING GLOBAL DEMAND FOR DIAGNOSTICS

- Range of diagnostics includes laboratory tests, imaging agents and diagnostic devices
- Majority of tests are performed in a pathology laboratory
- In the US, laboratory testing is the single highest-volume medical activity, with an estimated 13 billion tests performed each year *(KPMG)*
- The global laboratory test market was valued at \$US 69.6 billion in 2018 *(Grand View Research)*

TECH EXPANSION 2019 MILESTONES



ACQUISITION

- Completed acquisition of Sevident's novel molecular capture platform (SIEN-NET™), accessing the rapidly growing liquid biopsy and exosome space



POTENTIAL COLLABORATORS

- Enabled a wide range of engagement with potential collaborators for the joint development of therapeutic and diagnostic applications



ANNOUNCED TWO COLLABORATIONS

- Pancreatic Cancer diagnostic – Minomic International
- Exosome based therapeutic treatment - VivaZome


hTERT 2019 MILESTONES



GEOGRAPHICAL EXPANSION

Distribution initiated in:

- Korea
- Singapore
- Brazil



NEW DISTRIBUTORS FOR hTERT

Actively recruiting in:

- EU
- South Africa
- India



USA ADOPTION

- Driving increased adoption in the USA, increasing application support for StatLab
- Additional studies planned to support adoption

hTERT TEST: ADDRESSING AN UNMET NEED IN BLADDER CANCER DETECTION

THE UNMET NEED

- Current routine test has **low sensitivity** and **25% are inconclusive**

THE SIENNA SOLUTION

- Sienna's hTERT test used in conjunction with current test
- Provides additional information to **improve sensitivity**
- **Reduces inconclusive results**
- Requires no additional equipment
- Provides profitable revenue through existing reimbursement (USA)

“TESTING UROTHELIAL CELLS FOR THE PRESENCE OF HTERT IS A GREAT IMPROVEMENT OVER URINE CYTOLOGY ALONE... AS IT MAY BE AN INDICATION OF AN EARLY STAGE MALIGNANCY.”

*DR MICHAEL CHOI
CYTOPATHOLOGIST*




SIEN-NET™

A technology platform to enhance liquid biopsy testing

- Liquid biopsies are becoming the new gold standard in non-invasive cancer diagnostics
- SIEN-NET™ has the potential to revolutionise liquid biopsy sample preparation
- SIEN-NET™ platform is flexible and can capture and isolate **most biomarkers** from a broad range of body fluids **rapidly, specifically and in a scalable form**
- An important application of SIEN-NET™, which we have already developed, is EXO-NET™
- EXO-NET™ is specifically designed to capture and purify exosomes in human samples

EXOSOMES


- Exosomes are tiny particles shed from cells, including cancer cells, into the blood stream and other body fluids
- Exosomes are rich in host cell-associated proteins, nucleic acids and lipids giving us a deep insight into what's going on in the cancer cell
- ***“Exosomes are a cancer cell’s own ‘liquid biopsy’”***



- Appendix 1

EXO-NET™

Nano Engineered Technology for capture and isolation of exosomes



- EXO-NET™ is a specialised form of SIEN-NET™, specifically designed to capture exosomes from body fluids
- EXO-NET™ matrix comprises several antibodies that bind to common exosome-associated proteins providing a 3D matrix
- Can capture exosomes from blood in <30 minutes
- Scalable
- Outperforms other exosome isolation methods

SIENNA AND MINOMIC COLLABORATE ON PANCREATIC CANCER TEST

- Strong evidence that the protein **GPC-1 on exosomes** is significantly elevated in pancreatic cancer patients
- Sienna will utilise its proprietary EXO-NET™ exosome capture technology to isolate exosomes and Minomic will use its proprietary anti-GPC-1 antibody in a pilot study to test the feasibility of developing a proprietary pancreatic cancer assay



A diagnostic test that detects asymptomatic premalignant or early malignant tumors and predicts the response to treatment would greatly benefit pancreatic cancer patients

SIENNA AND MINOMIC COLLABORATE ON PANCREATIC CANCER TEST

Why Pancreatic Cancer?

- Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of approximately 9%
- 80–85% of cases at initial diagnosis present with unresectable advanced or metastatic disease
- Median survival time for these patients is 3–14 months
- In the USA, it is estimated there will be 56,770 new cases of pancreatic cancer and 45,750 deaths in 2019

<https://www.cancer.net/cancer-types/pancreatic-cancer/statistics>



A diagnostic test that detects asymptomatic premalignant or early malignant tumors and predicts the response to treatment would greatly benefit pancreatic cancer patients



sienna
CANCER DIAGNOSTICS

SIENNA & VIVAZOME EVALUATING EXO- NET™

- VivaZome is developing exosome-based therapies for debilitating and/or life-threatening disorders
- Initial therapy treatment for Critical Limb Ischemia (CLI) – 4M patients worldwide
- Estimated treatment cost of CLI is over \$10B pa in the US
- VivaZome will utilise Sienna's proprietary EXO-NET™ technology to isolate exosomes that will be used as a treatment for CLI
- Companies have agreed to evaluate other applications for the SIEN-NET™ platform
- Therapeutic applications for SIEN-NET™ open a "high value" opportunity for Sienna

COMPANY HIGHLIGHTS

- ✓ Track record in successfully commercialising new diagnostic technologies
- ✓ Experienced in acquisitions, licensing & deal making
- ✓ First commercial product now in-market, with growing global distributor network
- ✓ SIEN-NET™ platform technology with broad application across the fast-growing liquid biopsy market
- ✓ Building a pipeline of diagnostic tests in cancer areas of great unmet need – with more to follow



CONTACT DETAILS

SIENNA CANCER DIAGNOSTICS

Carl Stubbings

Chief Executive Officer & Managing Director

cstubbings@siennadiagnostics.com.au

Tony Di Pietro

Chief Financial Officer & Company Secretary

tdipietro@siennadiagnostics.com.au

INVESTOR RELATIONS

Kyahn Williamson

Head of Investor Communication – WE Communications

(03) 9866 4722

kwilliamson@we-worldwide.com

DISCLAIMER

This document has been prepared by Sienna Cancer Diagnostics (Sienna) and comprises written materials/slides for a presentation concerning Sienna. This presentation has been prepared by Sienna for professional investors. The information contained in this presentation is for information purposes only and does not constitute an offer or solicitation to sell or to issue, or arrange to sell or issue, securities or other financial products.

Any such offer or solicitation will be made only by means of a confidential information memorandum and in accordance with applicable securities and other laws. The information contained in this presentation is not investment or financial product advice, is not intended to be used as the basis for making an investment decision, and no specific recommendations are intended. The presentation has been prepared without taking into account the investment objectives, financial situation or particular need of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in the presentation.

To the maximum extent permitted by law, none of Sienna, its related companies and their respective directors, employees or advisers, nor any other person accepts any liability, including, without limitation, any liability arising out of fault. Certain statements in this presentation are forward looking statements. These forward looking statements speak only as at the date of this presentation. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward looking statements contained in this presentation are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.